Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (NASDAQ: CRTX), founded in 2000 and based in Cary, N.C., is a specialty pharmaceutical company focused on the respiratory, hospital, and related specialty sectors. The company's strategy revolves around targeting therapeutic niches within these markets, promoting current products to high-prescribing doctors through its respiratory sales force, and licensing or acquiring rights to branded products protected by patents or trade secrets. In 2012, the company received a $30.00M post-IPO debt investment from Chiesi Farmaceutici. Cornerstone Therapeutics aims to capitalize on existing businesses and create new prospects within its targeted sectors. It is committed to developing and marketing products, as well as advancing its development initiatives to expand a strong pipeline. Additionally, the company generates revenue by marketing approved generic products through its wholly owned subsidiary, Aristos Pharmaceuticals, Inc. Cornerstone Therapeutics' focus on niche markets, patent-protected products, and development initiatives positions it well for sustained growth and value generation. The strategic investment from Chiesi Farmaceutici signals confidence in the company's potential and its ability to make a significant impact in the pharmaceutical industry.